Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Regulatory

Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo Rivalry

 April 1, 2026

BioSpace

The FDA approved Eli Lilly’s orforglipron–to be known as Foundayo–on Wednesday, officially igniting what analysts believe will be a fierce rivalry with Novo Nordisk’s oral Wegovy.

RegulatoryMetabolic & GLP-1Read full story

Post navigation

FDA Approves First New Molecular Entity Under National Priority Voucher Program →
← Lilly bags FDA okay for Wegovy pill rival orforglipron

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com